Vivpro Corporation, a fast growing R&D intelligence and strategy provider, has appointed Dr. Pravin Jadhav PhD MPH as Chief Executive Officer (CEO). Dr. Jadhav is a leader in innovative product strategy and digital transformation. He will be responsible for managing Vivpro’s product and growth strategy. He will also spearhead creating broader demand and increasing knowledge and awareness of R&D intelligence as well as how Vivpro can help develop a winning product strategy faster. He will chair the Vivpro board as well as scientific advisory board (SAB).

"We are excited that Dr. Jadhav has agreed to guide Vivpro through the next phase of product and growth strategy to reimagine drug development," said Dr. Katie Laessig, Scientific Advisory Board Member at Vivpro Corporation and SVP of Global Regulatory Affairs at Antios Therapeutics. "I look forward to working with Pravin again. Pravin is an expert product developer with a keen mindset towards innovative drug development strategies.He has a well-rounded, unparalleled experience in regulatory science and pharmaceutical drug development. We hope to leverage Pravin’s experience to take Vivpro to its new heights and fulfill our vision of reimagining drug development."

"Vivpro is one of the most unique companies that I have seen. Vivpro is revolutionizing the pharmaceutical industry at the intersection of technology and therapeutics. I believe. Vivpro is uniquely qualified to innovate and reimagine drug development." said Dr. Pravin Jadhav, "I look forward to working with and leading the Vivpro team."